C4 Therapeutics, Inc. Restructuring and Related Cost, Cost Incurred to Date
C4 Therapeutics, Inc. (CCCC) had Restructuring and Related Cost, Cost Incurred to Date of $2.40 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2025-11-06
- 2025-09-30: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
- 2025-06-30: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
- 2025-03-31: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
- 2024-09-30: Restructuring and Related Cost, Cost Incurred to Date $2.40M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2025-09-30 | $2.40M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.40M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.40M 10-Q · filed 2025-05-07 |
| 2024-09-30 | $2.40M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $2.40M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $2.40M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |